Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Inclusion Criteria: * Male or female patients aged between 18 to 65 years. * Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening): 1. Fever (body temperature \> 38.0 °C (100.4 °F) measured orally) 2. Shortness of breath 3. New onset or increased cough with or without sputum production. 4. Chest pain. * Have radiographically documented bacterial pneumonia: 1. Infiltrates in a unilateral, lobar distribution 2. Diffuse opacities or white condensed area 3. The alveoli fill with white inflammatory fluid Exclusion Criteria: * Patients with severe pneumonia (Clinical \& Radiological Assessment) * Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.) * Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc. * History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs. * Intake of an antibiotic within the last 48 hours before study admission. * History of hospitalization within the last 28 days. * Patients in pregnancy and lactational state. * Patients with Renal impairment (screening eGFR \< 30mL/min). * Significant hepatic impairment (Alanine aminotransferase \> three times the upper limit of normal). * Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc. * Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids). * Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment. * Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.